Bipolar DisorderDepressive DisordersMajor Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)SuicidalitySafety & Risk ManagementEsketamineKetamine

Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis

This systemic review and meta-analysis (2020) of 24 clinical trials (n=1877) assessed the comparative efficacy and tolerability of racemic and esketamine for the treatment of unipolar and bipolar major depression. The authors found that intravenous ketamine appeared to be more efficacious than intranasal esketamine for the treatment of depression.

Authors

  • Carlos Zarate

Published

Journal of Affective Disorders
meta Study

Abstract

Background

Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression. However, the comparative performance of different formulations of ketamine is less clear.

Objectives

This study aimed to assess the comparative efficacy and tolerability of racemic and esketamine for the treatment of unipolar and bipolar major depression.

Design

Systematic review and meta-analysis.Data sources: We searched PubMed, MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Clinical Trials, and the Cochrane Database of Systematic Reviews for relevant studies published since database inception and December 17, 2019.Study eligibility criteria: We considered randomized controlled trials examining racemic or esketamine for the treatment of unipolar or bipolar major depression.

Outcomes

Primary outcomes were response and remission from depression, change in depression severity, suicidality, retention in treatment, drop-outs, and drop-outs due to adverse events.

Analysis

Evidence from randomized controlled trials was synthesized as rate ratios (RRs) for treatment response, disorder remission, adverse events, and withdrawals and as standardized mean differences (SMDs) for change in symptoms, via random-effects meta-analyses.

Findings

24 trials representing 1877 participants were pooled. Racemic ketamine relative to esketamine demonstrated greater overall response (RR = 3.01 vs. RR = 1.38) and remission rates (RR = 3.70 vs. RR = 1.47), as well as lower dropouts (RR = 0.76 vs. RR = 1.37).

Conclusions

Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.

Available with Blossom Pro

Research Summary of 'Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis'

Introduction

Ketamine's rapid antidepressant effects at subanaesthetic doses have attracted attention as an option for treatment-resistant depression, but its dissociative effects, abuse potential and the logistical challenges of intravenous administration have prompted investigation of alternative formulations and routes. One such alternative is the S-enantiomer esketamine, which is more potent at the NMDA receptor and is available as an intranasal spray; intranasal esketamine received regulatory approval for treatment-resistant depression in 2019. Despite these developments, uncertainty remains about comparative efficacy, tolerability and acceptability between intravenous racemic (R,S)-ketamine and intranasal esketamine, and no robust head-to-head clinical trials had been completed at the time of this review. Bahji and colleagues set out to synthesise the randomised controlled trial evidence to compare racemic ketamine and esketamine for unipolar and bipolar depression. The study aimed to estimate comparative effects on remission and symptom change, to examine safety and acceptability (including all-cause and adverse-event withdrawals), and to explore moderators such as treatment resistance, trial design and mode of administration using systematic review and meta-analysis methods registered on the Open Science Framework and performed in accordance with PRISMA guidance.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (30)

Papers cited by this study that are also in Blossom

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

Ari, A., Abdallah, C. G., Sanacora, G. et al. · Annual Review of Medicine (2014)

Efficacy and safety of ketamine in bipolar depression: A systematic review

Alberich, S., Martínez-Cengotitabengoa, M., López, P. et al. · Revista de Psiquiatría y Salud Mental (2017)

1 cited
Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)

Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice

Bobo, W. V., Vande Voort, J. L., Croarkin, P. E. et al. · Depression and Anxiety (2016)

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Diazgranados, N., Ibrahim, L., Brutsche, N. E. et al. · JAMA Psychiatry (2010)

943 cited
Ketamine administration in depressive disorders: a systematic review and meta-analysis

Fond, G., Loundou, A., Macgregor, A. et al. · Psychopharmacology (2014)

159 cited
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial

Grunebaum, M. F., Galfalvy, H. C., Choo, T. H. et al. · American Journal of Psychiatry (2018)

371 cited
Show all 30 references
151 cited
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression

Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J. et al. · Bipolar Disorders (2014)

Administration of ketamine for unipolar and bipolar depression

Kraus, C., Rabl, U., Vanicek, T. et al. · International Journal of Psychiatry in Clinical Practice (2017)

Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain

López-Díaz, A., Fernández-González, J. L., Luján-Jiménez, J. E. et al. · Therapeutic Advances in Psychopharmacology (2017)

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

Murrough, J. W., Perez, A. M., Pillemer, S. et al. · Biological Psychiatry (2012)

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

Newport, D. J., Carpenter, L. L., Mcdonald, W. M. et al. · American Journal of Psychiatry (2015)

Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression

Sos, P., Klirova, M., Novák, T. et al. · Neuropsychiatric Disease And Treatment (2013)

Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression

Su, T. P., Chen, M. H., Li, C. T. et al. · Neuropsychopharmacology (2017)

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis

Wilkinson, S. T., Ballard, E. D., Bloch, M. H. et al. · American Journal of Psychiatry (2017)

Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism

Williams, N. R., Heifets, B. D., Bentzley, B. S. et al. · Molecular Psychiatry (2019)

Mechanisms of ketamine action as an antidepressant

Zanos, P., Gould, T. D. · Molecular Psychiatry (2018)

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, P. J., Morris, P. J. et al. · Nature (2016)

Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

Zarate, C. A., Brutsche, N. E., Ibrahim, L. et al. · Biological Psychiatry (2012)

757 cited

Cited By (18)

Papers in Blossom that reference this study

Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis

Fountoulakis, K. N., Saitis, A., Schatzberg, A. F. · American Journal of Psychiatry (2025)

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems

Gent, E. M., Bryan, J. W., Cleary, M. A. et al. · Journal of Psychopharmacology (2024)

The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database

Jiang, Y., Du, Z., Shen, Y. et al. · European Archives of Psychiatry and Clinical Neuroscience (2023)

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression

Rodgers, A., Bahceci, D., Davey, C. G. et al. · Australian and new-zealand Journal of Psychiatry (2023)

5 cited
19 cited
Show all 18 papers
Ketamine for suicidality: an umbrella review

Shamabadi, A., Ahmadzade, A., Hasanzadeh, A. · British Journal of Clinical Pharmacology (2022)

Pharmacogenomics of ketamine: A systematic review

Meshkat, S., Rodrigues, N. B., Vincenzo, J. D. D. et al. · Journal of Psychiatric Research (2022)

Ketamine for bipolar depression: a systematic review

Bahji, A., Zarate, C. A., Vazquez, G. H. · International Journal of Neuropsychopharmacology (2021)

Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials

Muthukumaraswamy, S., Forsyth, B., Lumley, T. · Expert Review of Clinical Pharmacology (2021)

113 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.